Want to see AU:NUZ full AI Analyst Report?
Top Page
Pharmaust Limited
(Sydney:NUZ)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.09
â–Ľ(-14.00% Downside)
Action:Upgraded
Date:09/10/26
The score is held back primarily by very weak fundamentals (no recent revenue, ongoing large losses, and heavy cash burn implying continued financing dependence). Technicals provide some support with price trading above key moving averages, but momentum indicators are mixed. Valuation is also constrained by a negative P/E and no dividend yield data.
Positive Factors
Improved Equity Base
The substantial increase in equity provides a larger capitalization cushion than the company had in 2025. This may improve resilience against ongoing losses, support access to funding, and give management more flexibility while pursuing its biotechnology activities.
Negative Factors
No Recent Revenue
The absence of reported revenue across three consecutive years leaves the company without demonstrated commercial income to support operations. This weakens self-funding capacity, increases dependence on external capital, and makes future financial performance reliant on achieving renewed commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Equity Base
The substantial increase in equity provides a larger capitalization cushion than the company had in 2025. This may improve resilience against ongoing losses, support access to funding, and give management more flexibility while pursuing its biotechnology activities.
Read all positive factors
Pharmaust Limited (NUZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$68.08M
Dividend YieldN/A
Average Volume (3M)290.32K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue GrowthN/A
EPS Growth47.31%
CountryAU
Employees36
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding791,652,340
10 Day Avg. Volume184,150
30 Day Avg. Volume290,321
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.87
Price to Sales (P/S)2.08
P/FCF Ratio-2.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.20Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmaust Limited Business Overview & Revenue Model
Company Description
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate i...
How the Company Makes Money
null...
Pharmaust Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.59M | 0.00 | 0.00 | 873.65K | 3.38M |
| Gross Profit | 17.59M | 0.00 | -1.64K | -929.53K | -223.52K |
| EBITDA | -27.75M | -18.48M | -9.45M | -9.13M | -1.30M |
| Net Income | -10.72M | -16.59M | -9.03M | -9.03M | -1.71M |
Balance Sheet | |||||
| Total Assets | 23.70M | 4.36M | 11.12M | 6.13M | 6.13M |
| Cash, Cash Equivalents and Short-Term Investments | 12.71M | 4.18M | 9.72M | 2.71M | 2.71M |
| Total Debt | 3.31M | 0.00 | 0.00 | 1.05M | 1.39M |
| Total Liabilities | 10.97M | 1.54M | 896.61K | 2.24M | 2.23M |
| Stockholders Equity | 12.73M | 2.82M | 10.23M | 3.89M | 7.84M |
Cash Flow | |||||
| Free Cash Flow | -15.08M | -14.29M | -5.17M | -1.60M | -1.38M |
| Operating Cash Flow | -15.07M | -14.29M | -5.17M | -1.56M | -1.33M |
| Investing Cash Flow | -8.22K | -21.55K | -1.17M | -34.93K | -43.38K |
| Financing Cash Flow | 23.51M | 8.76M | 13.34M | 1.89M | 770.99K |
Pharmaust Limited Technical Analysis
Positive
0.10
Price Trends
0.08
Positive
0.07
Positive
0.08
Positive
Market Momentum
<0.01
Positive
58.45
Neutral
69.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NUZ, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 58.45 is Neutral, neither overbought nor oversold. The STOCH value of 69.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NUZ.
Pharmaust Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$68.08M | -4.91 | -102.07% | ― | ― | 47.31% | |
47 Neutral | AU$153.48M | -1.61 | -1189.87% | ― | 53.78% | -206.24% | |
47 Neutral | AU$110.10M | -6.95 | 84.67% | ― | ― | 42.51% | |
44 Neutral | AU$33.90M | -0.43 | -98.86% | ― | ― | -27.73% | |
44 Neutral | AU$60.62M | -7.68 | -44.93% | ― | ― | 25.27% | |
41 Neutral | AU$27.63M | -0.31 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
AU:NUZ
Pharmaust Limited
0.09
-0.03
-26.50%
AU:PAR
Paradigm Biopharmaceuticals
0.25
-0.15
-37.97%
AU:IMM
Immutep Ltd
0.02
-0.26
-91.79%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
15.22%
AU:BOT
Botanix Pharmaceuticals Limited
0.01
-0.12
-92.31%
AU:RCE
Recce Pharmaceuticals Ltd.
0.36
-0.04
-10.00%
Pharmaust Limited Corporate Events
Neurizon Therapeutics Halts Trading Ahead of Capital Raising Outcome
Oct 28, 2026
Neurizon Therapeutics has requested and received a trading halt in its shares on the ASX, effective from the open of trading on 29 October 2026. The halt is expected to remain in place until either normal trading resumes on Monday, 2 November 2026...
Neurizon Advances NUZ-001 ALS Program With Full Trial Enrolment and Strengthened Funding
Oct 27, 2026
Neurizon completed enrolment of 250 participants in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial at 78 U.S. sites, accelerating the expected topline data to late Q2 2027 and maintaining statistical power without increasing funding needs. T...
Neurizon Therapeutics Sets Hybrid AGM, Moves to Digital-First Shareholder Communications
Oct 26, 2026
Neurizon Therapeutics has called its Annual General Meeting for 25 November 2026 at 2.00pm AEDT, to be conducted as a hybrid event at legal firm Gilbert + Tobin’s Melbourne offices and via an online video-conferencing facility. The company h...
Neurizon Resets 2026 AGM Date and Promotes Investor Engagement
Oct 22, 2026
Neurizon Therapeutics has rescheduled its 2026 Annual General Meeting to 25 November 2026 in Melbourne, with further details to be issued in a forthcoming Notice of Meeting. The board has signalled its intention to use the AGM as a forum to engage...
Neurizon Therapeutics Trims Future Dilution as Options and Rights Lapse
Oct 13, 2026
Neurizon Therapeutics Limited has announced the cessation of a tranche of equity-linked securities following the lapse of conditional rights. A total of 4,256,000 options expiring in June 2032 and 1,140,000 performance rights have lapsed after the...
Neurizon updates investors on NUZ-001 strategy and plans ALS trial milestones
Oct 6, 2026
Neurizon Therapeutics has released an updated investor presentation outlining its strategy as it progresses lead asset NUZ-001 through late-stage clinical development, including a 250-participant Phase 2/3 HEALEY ALS Platform Trial with topline da...
FDA Feedback Positions Neurizon’s ALS Trial as Potentially Registrational
Oct 5, 2026
Neurizon Therapeutics has received written feedback from the U.S. Food and Drug Administration indicating that positive Phase 2/3 results from the HEALEY ALS Platform Trial of its lead ALS candidate NUZ-001 could support a traditional approval pat...
Neurizon Director Boosts Shareholding in On-Market Purchase
Sep 17, 2026
Neurizon Therapeutics has disclosed a change in director Sergio Duchini’s holdings, reflecting an on-market purchase of additional fully paid ordinary shares. The transaction underscores ongoing insider investment in the company and may be v...
Neurizon Therapeutics Redeems 1 Million Convertible Notes Without Conversion
Sep 15, 2026
Neurizon Therapeutics Limited has announced the cessation of 1,000,000 NUZAA convertible notes following their repayment or redemption without conversion on 14 September 2026. The move reduces outstanding convertible debt and may simplify the comp...
Neurizon Cuts Convertible Notes and Locks In Standstill as HEALEY ALS Trial Funding Secured
Sep 10, 2026
Neurizon Therapeutics will redeem 1,000,000 convertible notes held by Obsidian for total consideration of US$1,150,000, cutting the outstanding notes to 750,000 and securing a two-month agreement that Obsidian will not sell Neurizon shares. The bo...
Neurizon Therapeutics Seeks ASX Quotation for 7.4 Million New Shares
Sep 10, 2026
Neurizon Therapeutics Limited has applied for quotation of 7,436,765 new ordinary fully paid shares on the ASX, to be issued on September 10, 2026. The application, lodged as an Appendix 2A, reflects additional securities resulting from the exerci...
NIH Backs Neurizon’s NUZ-001 ALS Access Program With Multimillion-Dollar Grant
Sep 9, 2026
Neurizon Therapeutics has secured participation in a multimillion-dollar, multi-year NIH-funded Expanded Access Protocol that will allow up to 200 people in the U.S. living with ALS, who are ineligible for clinical trials, to receive its lead inve...
Neurizon names seasoned pharma executive Chris Bremer as CEO ahead of key ALS trial readout
Sep 6, 2026
Neurizon Therapeutics has appointed Dr Chris Bremer as Chief Executive Officer, effective 1 October 2026, as the company advances its lead ALS candidate NUZ-001 through a registrational Phase 2/3 trial. Bremer will initially serve as CEO without j...
Neurizon Therapeutics Expands ASX Quoted Share Base
Aug 26, 2026
Neurizon Therapeutics Limited has applied for quotation on the ASX of 9,116,092 ordinary fully paid shares under the code NUZ.The new securities, issued on August 26, 2026, arise from the exercise or conversion of existing options or other convert...
Neurizon Therapeutics files ASX governance disclosure for 2026
Aug 25, 2026
Neurizon Therapeutics Limited has lodged its corporate governance statement and completed Appendix 4G for the financial year ended 30 June 2026, confirming compliance with ASX Listing Rules. The statement, approved by the board as at 25 August 202...
Neurizon Therapeutics Narrows Loss and Strengthens Balance Sheet in 2026
Aug 25, 2026
Neurizon Therapeutics Limited has reported a sharply improved financial position for the year ended 30 June 2026, despite remaining loss-making. Other income surged by 844.2% to $17.77 million, helping cut the after-tax loss attributable to owners...
Neurizon Therapeutics Issues Large Tranche of Unquoted Incentive Securities
Aug 24, 2026
Neurizon Therapeutics Limited has notified the market of the issuance of a substantial tranche of unquoted equity securities under its employee incentive scheme. The company will issue more than 14 million performance rights and approximately 8 mi...
Neurizon strengthens Elanco alliance with appointment of new Board observer
Aug 13, 2026
Neurizon Therapeutics has appointed Dr. Steve Nanchen, Senior Advisor for External Innovation at Elanco Animal Health, as a non-voting Board Observer, reinforcing the strategic ties between the two companies. The move follows Neurizon’s excl...
Neurizon accelerates ALS trial and secures supply deal as funding base strengthens
Jul 31, 2026
Neurizon reported a strong June quarter marked by rapid clinical progress in its NUZ‑001 program within the Phase 2/3 HEALEY ALS Platform Trial, expanding Regimen I from 160 to 250 participants while maintaining statistical power and funding...
Neurizon Secures $17.5m Non-Dilutive R&D Financing to Fund ALS Trial
Jul 31, 2026
Neurizon Therapeutics has entered a strategic RD financing facility of up to $17.5 million with the Dare Capital Loan Fund, secured solely against its Australian RD Tax Incentive refunds. An initial drawdown of about $8 million tied to the FY2026 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.